Breakthrough Potential for Israeli Diabetes Care
What’s happening:
New findings from the prestigious American College of Cardiology (ACC) conference reveal that the oral medication Rybelsus, marketed by Novo Nordisk, reduces the risk of significant cardiovascular events by 14% in patients with type 2 diabetes. This development positions Rybelsus as a significant contender in diabetes management, particularly with its inclusion in Israel’s health basket for diabetes patients.
Why it matters:
Israel has been at the forefront of adopting medical innovations to enhance public health. Rybelsus, with its remarkable cardiovascular benefits, could significantly impact the way diabetes is managed in Israel, providing a simple and non-invasive treatment option. This aligns perfectly with Israel’s commitment to leveraging advanced medical solutions for enhancing the life quality of its citizens.
The Details:
The SOUL study, which is pioneering in exploring the cardiovascular advantages of an oral GLP-1 receptor agonist, showcased that Rybelsus’s active ingredient emulates GLP-1 hormone properties to bind effectively to receptors. This leads to a notable decrease not just in cardiovascular deaths but also nonfatal heart attacks by 26% among its users.
Further involving Israel’s medical arena, the heart of the study incorporated significant contributions from Israeli patients, fortifying the understanding and practicality of introducing the treatment on a wider scale with promising results, thanks notably to Sheba Medical Center’s leading involvement.
The Israeli Connection:
According to Professor Michael Shechter of Sheba Medical Center, Israel was instrumental in conducting the study, presenting 80 patients from various national medical facilities. This participation underscores Israel’s pivotal role in innovatively tackling prominent health challenges, aligning with Shechter’s emphasis on simultaneous treatments for heart disease and diabetes, notably common covariances.
What’s next:
With these groundbreaking results, Novo Nordisk is primed to seek extended approval across the US and Europe, potentially widening Rybelsus’s availability. Coupled with Novo Nordisk’s strategic efforts to counter competition, notably from Eli Lilly, this function enhancement could conveniently serve Israel’s ambitious efforts to provide alternative healthcare solutions and boost patient well-being in an evolving global healthcare landscape.
This story was first published on ynetnews.com.